T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Cencora
COR
$59.2B
| $26.8M | ﹤0.01% |
303,083
+20,541
| +7% | +$1.81M |
|
977
Karyopharm Therapeutics
KPTI
$45.1M
| $26.8M | ﹤0.01% |
92,983
+81,666
| +722% | +$22.5M |
|
978
Ingevity
NGVT
$2.59B
| $26.7M | ﹤0.01% |
758,592
-4,866
| -0.6% | -$284K |
|
|
EVOP
979
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $26.6M | ﹤0.01% |
1,736,740
+29,243
| +2% | +$721K |
|
980
Amcor
AMCR
$21.4B
| $26.5M | ﹤0.01% |
653,187
+48,332
| +8% | +$2.32M |
|
981
CBRE Group
CBRE
$44B
| $26.4M | ﹤0.01% |
699,578
+51,203
| +8% | +$2.83M |
|
982
Hewlett Packard
HPE
$79.2B
| $26.4M | ﹤0.01% |
2,715,809
+258,503
| +11% | +$3.39M |
|
983
Evergy
EVRG
$19.3B
| $26.3M | ﹤0.01% |
478,589
-1,971,557
| -80% | -$130M |
|
984
Extra Space Storage
EXR
$31.6B
| $26.2M | ﹤0.01% |
274,106
+20,454
| +8% | +$2.13M |
|
985
Equity Bancshares
EQBK
$1.07B
| $26.2M | ﹤0.01% |
1,519,115
-1,427
| -0.1% | -$35.9K |
|
986
John B. Sanfilippo & Son
JBSS
$1.01B
| $26.1M | ﹤0.01% |
291,556
+7,277
| +3% | +$587K |
|
987
LyondellBasell Industries
LYB
$20.2B
| $26M | ﹤0.01% |
523,952
+36,813
| +8% | +$2.71M |
|
988
NeoGenomics
NEO
$2.11B
| $25.9M | ﹤0.01% |
939,543
+881,841
| +1,528% | +$26.4M |
|
989
Prestige Consumer Healthcare
PBH
$2.43B
| $25.9M | ﹤0.01% |
706,800
-153,962
| -18% | -$5.98M |
|
990
Universal Health Services
UHS
$10.1B
| $25.9M | ﹤0.01% |
261,656
+14,370
| +6% | +$1.82M |
|
991
Perdoceo Education
PRDO
$1.99B
| $25.9M | ﹤0.01% |
2,400,685
+34,974
| +1% | +$544K |
|
992
Best Buy
BBY
$18B
| $25.9M | ﹤0.01% |
453,756
+37,115
| +9% | +$2.94M |
|
993
J.M. Smucker
SJM
$12.9B
| $25.6M | ﹤0.01% |
230,283
+18,289
| +9% | +$1.96M |
|
994
Boyd Gaming
BYD
$6.05B
| $25.5M | ﹤0.01% |
1,770,542
-91,450
| -5% | -$2.34M |
|
995
Quanterix
QTRX
$135M
| $25.5M | ﹤0.01% |
1,387,324
-57,110
| -4% | -$1.3M |
|
996
iShares Russell 1000 Value ETF
IWD
$84.3B
| $25.1M | ﹤0.01% |
+253,200
| New | +$31.6M |
|
997
Nektar Therapeutics
NKTR
$2.57B
| $25.1M | ﹤0.01% |
93,641
+27,971
| +43% | +$8.65M |
|
998
First American
FAF
$7.56B
| $25M | ﹤0.01% |
590,220
+222,147
| +60% | +$12.7M |
|
999
Mid-America Apartment Communities
MAA
$15.6B
| $24.9M | ﹤0.01% |
241,649
+19,414
| +9% | +$2.52M |
|
1000
Labcorp
LH
$26.2B
| $24.7M | ﹤0.01% |
227,082
+17,719
| +8% | +$2.55M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.